Literature DB >> 30306073

Molecular basis of cystic fibrosis: from bench to bedside.

Maria Cristina Dechecchi1, Anna Tamanini1, Giulio Cabrini2.   

Abstract

Cystic fibrosis (CF), is an autosomal recessive disease affecting different organs. The lung disease, characterized by recurrent and chronic bacterial infection and inflammation since infancy, is the main cause of morbidity and precocious mortality of these individuals. The innovative therapies directed to repair the defective CF gene should account for the presence of more than 200 disease-causing mutations of the CF transmembrane conductance regulator (CFTR) gene. The review will recall the different experimental approaches in discovering CFTR protein targeted molecules, such as the high throughput screening on chemical libraries to discover correctors and potentiators of CFTR protein, dual-acting compounds, read-through molecules, splicing defects repairing tools, CFTR "amplifiers".

Entities:  

Keywords:  CFTR potentiators; Cystic fibrosis (CF); cystic fibrosis transmembrane conductance regulator correctors (CFTR correctors); personalized medicine

Year:  2018        PMID: 30306073      PMCID: PMC6174194          DOI: 10.21037/atm.2018.06.48

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  148 in total

1.  Structure-activity relationships of cyanoquinolines with corrector-potentiator activity in ΔF508 cystic fibrosis transmembrane conductance regulator protein.

Authors:  John M Knapp; Alex B Wood; Puay-Wah Phuan; Michael W Lodewyk; Dean J Tantillo; A S Verkman; Mark J Kurth
Journal:  J Med Chem       Date:  2012-01-23       Impact factor: 7.446

2.  Vx-809/Vx-770 treatment reduces inflammatory response to Pseudomonas aeruginosa in primary differentiated cystic fibrosis bronchial epithelial cells.

Authors:  Manon Ruffin; Lucie Roussel; Émilie Maillé; Simon Rousseau; Emmanuelle Brochiero
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-12-20       Impact factor: 5.464

3.  Potential-sensitive response mechanism of diS-C3-(5) in biological membranes.

Authors:  G Cabrini; A S Verkman
Journal:  J Membr Biol       Date:  1986       Impact factor: 1.843

4.  Trimethylangelicin promotes the functional rescue of mutant F508del CFTR protein in cystic fibrosis airway cells.

Authors:  Maria Favia; Maria T Mancini; Valentino Bezzerri; Lorenzo Guerra; Onofrio Laselva; Anna C Abbattiscianni; Lucantonio Debellis; Stephan J Reshkin; Roberto Gambari; Giulio Cabrini; Valeria Casavola
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-05-09       Impact factor: 5.464

5.  Cell-based assay for high-throughput quantitative screening of CFTR chloride transport agonists.

Authors:  L V Galietta; S Jayaraman; A S Verkman
Journal:  Am J Physiol Cell Physiol       Date:  2001-11       Impact factor: 4.249

6.  Anti-inflammatory effect of miglustat in bronchial epithelial cells.

Authors:  Maria Cristina Dechecchi; Elena Nicolis; Caroline Norez; Valentino Bezzerri; Monica Borgatti; Irene Mancini; Paolo Rizzotti; Carla M P Ribeiro; Roberto Gambari; Frederic Becq; Giulio Cabrini
Journal:  J Cyst Fibros       Date:  2008-09-23       Impact factor: 5.482

7.  Identification of the cystic fibrosis gene: chromosome walking and jumping.

Authors:  J M Rommens; M C Iannuzzi; B Kerem; M L Drumm; G Melmer; M Dean; R Rozmahel; J L Cole; D Kennedy; N Hidaka
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

8.  Synthesis and structure-activity relationship of aminoarylthiazole derivatives as correctors of the chloride transport defect in cystic fibrosis.

Authors:  Emanuela Pesce; Marta Bellotti; Nara Liessi; Sara Guariento; Gianluca Damonte; Elena Cichero; Andrea Galatini; Annalisa Salis; Ambra Gianotti; Nicoletta Pedemonte; Olga Zegarra-Moran; Paola Fossa; Luis J V Galietta; Enrico Millo
Journal:  Eur J Med Chem       Date:  2015-05-28       Impact factor: 6.514

9.  ΔF508 CFTR surface stability is regulated by DAB2 and CHIP-mediated ubiquitination in post-endocytic compartments.

Authors:  Lianwu Fu; Andras Rab; Li ping Tang; Zsuzsa Bebok; Steven M Rowe; Rafal Bartoszewski; James F Collawn
Journal:  PLoS One       Date:  2015-04-16       Impact factor: 3.240

10.  Effects of ivacaftor in patients with cystic fibrosis who carry the G551D mutation and have severe lung disease.

Authors:  Peter J Barry; Barry J Plant; Arjun Nair; Stephen Bicknell; Nicholas J Simmonds; Nicholas J Bell; Nadia T Shafi; Thomas Daniels; Susan Shelmerdine; Imogen Felton; Cedric Gunaratnam; Andrew M Jones; Alex R Horsley
Journal:  Chest       Date:  2014-07       Impact factor: 9.410

View more
  9 in total

1.  Cyclic Peptidyl Inhibitors against CAL/CFTR Interaction for Treatment of Cystic Fibrosis.

Authors:  Patrick G Dougherty; Jack H Wellmerling; Amritendu Koley; Jessica K Lukowski; Amanda B Hummon; Estelle Cormet-Boyaka; Dehua Pei
Journal:  J Med Chem       Date:  2020-12-14       Impact factor: 7.446

Review 2.  Membrane proteins enter the fold.

Authors:  Dagan C Marx; Karen G Fleming
Journal:  Curr Opin Struct Biol       Date:  2021-05-08       Impact factor: 7.786

3.  Lung ultrasound for the diagnosis of cystic fibrosis pulmonary exacerbation.

Authors:  Maryam Hassanzad; Arda Kiani; Atefeh Abedini; Hoseinali Ghaffaripour; Habib Emami; Niloufar Alizadeh; Ghazal Zoghi; Saeed Hashemi; Ali Akbar Velayati
Journal:  BMC Pulm Med       Date:  2021-11-08       Impact factor: 3.317

4.  Combined Treatment of Bronchial Epithelial Calu-3 Cells with Peptide Nucleic Acids Targeting miR-145-5p and miR-101-3p: Synergistic Enhancement of the Expression of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Gene.

Authors:  Chiara Papi; Jessica Gasparello; Matteo Zurlo; Alex Manicardi; Roberto Corradini; Giulio Cabrini; Roberto Gambari; Alessia Finotti
Journal:  Int J Mol Sci       Date:  2022-08-19       Impact factor: 6.208

Review 5.  Recent Strategic Advances in CFTR Drug Discovery: An Overview.

Authors:  Marco Rusnati; Pasqualina D'Ursi; Nicoletta Pedemonte; Chiara Urbinati; Robert C Ford; Elena Cichero; Matteo Uggeri; Alessandro Orro; Paola Fossa
Journal:  Int J Mol Sci       Date:  2020-03-31       Impact factor: 5.923

Review 6.  Synthesis and Therapeutic Applications of Iminosugars in Cystic Fibrosis.

Authors:  Anna Esposito; Daniele D'Alonzo; Maria De Fenza; Eliana De Gregorio; Anna Tamanini; Giuseppe Lippi; Maria Cristina Dechecchi; Annalisa Guaragna
Journal:  Int J Mol Sci       Date:  2020-05-09       Impact factor: 5.923

7.  Systematic genetic analysis of the MHC region reveals mechanistic underpinnings of HLA type associations with disease.

Authors:  Matteo D'Antonio; Joaquin Reyna; David Jakubosky; Margaret Kr Donovan; Marc-Jan Bonder; Hiroko Matsui; Oliver Stegle; Naoki Nariai; Agnieszka D'Antonio-Chronowska; Kelly A Frazer
Journal:  Elife       Date:  2019-11-20       Impact factor: 8.713

8.  Clinical Presentation of the c.3844T>C (p.Trp1282Arg, W1282R) Variant in Russian Cystic Fibrosis Patients.

Authors:  Nika V Petrova; Nataliya Y Kashirskaya; Stanislav A Krasovskiy; Elena L Amelina; Elena I Kondratyeva; Andrey V Marakhonov; Tatyana A Vasilyeva; Anna Y Voronkova; Victoria D Sherman; Evgeny K Ginter; Sergey I Kutsev; Rena A Zinchenko
Journal:  Genes (Basel)       Date:  2020-09-27       Impact factor: 4.096

9.  Serum inflammatory profiles in cystic fibrosis mice with and without Bordetella pseudohinzii infection.

Authors:  Paul M Litman; Alexander Day; Thomas J Kelley; Rebecca J Darrah
Journal:  Sci Rep       Date:  2021-09-02       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.